Protein that can stop the spread of breast cancer discovered

Apr 8, 2017 | | Say something

breast-cancer

Breast cancer is one of the most rampant forms of cancer today, and is seen as the main threat to life of women. While cancer can occur in men as well, which is frequently observed in women. According to recent statistics, breast cancer affects more women in urban areas than in people living in rural areas. But there is some good news, scientists have discovered a new protein called Erbin, which is believed to be an anti-tumor factor in aggressive breast cancer. One of the first known-oncogenes has a partner protein that helps breast cancer and proliferate when locked, so is cancer. The ErbB2 gene, commonly called HER2 is highly expressed in about 25 percent of breast cancers. Scientists have now discovered protein that is highly expressed in these cancers and essential for the support of breast cancer ErbB2.

Related Post:   You want to improve your immunity? Try Ayurveda

When scientists interfered with the interaction between the two in mice, tumor growth and spread to the lungs usual was inhibited. The team documented the expression of more than 171 in both cases of aggressive human breast cancer forms as well.

The findings point to a new therapeutic target for aggressive breast cancer and potentially a supplement for women who become resistant to Herceptin, or trastuzumab, the drug was given to ErbB2 positive patients, said corresponding author Dr. Lin Mei. In addition, Erbin could be a biomarker diagnostic doctors look at breast tissue biopsies.

Related Post:   Improving food insecurity and alleviate poverty affects clinical outcomes of HIV

Mei said yes Erbin could be a new goal: to disrupt interaction and would be therapeutic. Second, when a patient became resistant Herceptin because the extracellular domain of ErbB2 was lost, this approach should still be effective because of the critical interaction of the two.

The Food and Drug Administration approved Herceptin for women with metastatic breast cancer overexpressing ErbB2 or HER2 cancer in 1998 and in 2006, as an adjuvant treatment in early stage HER2-positive breast cancer. The study is published in the journal PNAS .

Source: ANI

Image source: Getty


Follow us on Facebook and Twitter for all the latest updates! For free daily health tips, subscribe to our bulletin .

Related Post:   You be careful with these 10 things that can cause liver disease

This article was originally published on thehealthsite, Read the original article here

You may also like:

Posted in: Breast Cancer, Cancer, Diseases & Conditions, In the news

Leave a Reply

Your email address will not be published. Required fields are marked *

==[Click 2x to Close X]==
Most Popular Today!